$PLPL Plandai Biotechnology, Inc. Is Taking On the

[b]$PLPL[/b] Plandai Biotechnology, Inc. Is Taking On the Malaria Parasite and Winning

NEW YORK, NY, [b][color=green]Jun 06, 2013[/color] [/b](Marketwired via COMTEX) -- Plandai Biotechnology, Inc. (OTCQB: PLPL) recently put one of the company's highly bioavailable products to work in a study to prove it can kill a deadly parasite. It was Plandai's Phytofare(TM) Catechin Complex, and it proved it can, in fact, be effective in killing the parasite. This is big news for a company that plans on using its products as an antimalarial drug target in the war on this worldwide disease that infects about 500 million people each year. Malaria is killing a staggering number of the people who do contract the disease. Of the 500 million infected, roughly 600 thousand of them will die.

Plandai Biotechnology, a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical and pharmaceutical, plans to enter into Phase II human clinical trials using Phytofare(TM) with the eventual goal being FDA approval of an antimalarial drug. The recently announced results of the study will go a long way to getting Plandai one step closer to submitting its application to the U.S. Food and Drug Administration requesting those human trials.

The study, conducted under the supervision of Dr. Sanjeev Krishna, a professor of molecular parasitology and medicine at St George's London School of Medicine, showed proof in analytical tests that Plandai's Phytofare(TM) Catechin Complex was effective in killing the malaria parasite, plasmodium falciparum. Dr. Krishna developed the tests that were conducted at St George's London School of Medicine at the Division of Cellular and Molecular Medicine, Centre for Infection.

In the study, the most dominant catechin, Epigallocatechin Gallate (EGCG) was isolated from Plandai's Phytofare(TM) extract and then had its effectiveness in killing the P. falciparum parasite compared against a purified EGCG extract.

Continue Reading to learn more about Plandai's trial results at www.stockmarketmediagroup.com/features.

About Stock Market Media Group

Stock Market Media Group, formerly Stock House Group, is a full service Investment Relations firm specializing in Research, Content Development and Awareness. The firm offers a platform for CEOs to tell their story through the media with its Feature Articles, Research Reports, and CEO Interviews. At the same time, the company is building a library of Research on its website for Investors to become better informed on small cap stocks. For more information www.stockmarketmediagroup.com.